1009107-27-0

Basic information

• Product Name: Daclatasvir Impurity 4
• Synonyms: Daclatasvir Impurity 4;Daclatasvir Impurity (RSSR-isomer);Daclatasvir Impurity A;N,N'-[[1,1'-Biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1R)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]biscarbamic Acid C,C'-Dimethyl Ester
• CAS NO: 1009107-27-0
• Molecular Formula: C40H50N8O6
• Molecular Weight: 738.875
• EINECS: -0
• Mol File: 1009107-27-0.mol

Chemical Properties

• Boiling Point: 1071.2±65.0 °C(Predicted)
• Appearance: /
• Density: 1.249±0.06 g/cm3(Predicted)
• PKA: 10.92±0.46(Predicted)
• CAS DataBase Reference: Daclatasvir Impurity 4(CAS DataBase Reference)
• NIST Chemistry Reference: Daclatasvir Impurity 4(1009107-27-0)
• EPA Substance Registry System: Daclatasvir Impurity 4(1009107-27-0)

Safety Data

• Hazardous Substances Data: 1009107-27-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Daclatasvir Impurity 4 is used as a drug candidate for the treatment of hepatitis C (HCV) due to its inhibitory effect on the HCV protein NS5A. It plays a crucial role in the development and formulation of Daclatasvir-based medications, ensuring the safety and efficacy of the final drug product.

Upstream product

• 1007882-23-6 methyl N-[(2S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate 
• 1007882-27-0 2-[(2S)-pyrrolidin-2-yl]-5-[4-(4-{2-[(2S)-pyrrolidin-2-yl]-1H-imidazol-5-yl}phenyl)phenyl]-1H-imidazole 
• 111398-44-8 N-methoxycarbonyl-L-valine 
• 1009119-83-8 1H-imidazole,5,5'-[1,1'-biphenyl]-4,4'-bis[2-(2S)-2-pyrrolidine-2yl hydrochloride] 
• 530-62-1 1,1'-carbonyldiimidazole 
• 1009119-83-8 methyl N-[(2S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate hydrochloride 
• 79-22-1 methyl chloroformate 

Downstream Products

• 1312335-96-8 C₄₀H₄₈Br₂N₈O₆ 

Relevant articles and documents

Micro-electro-flow reactor (μ-EFR) system for ultra-fast arene synthesis and manufacture of daclatasvir

The World Health Organization (WHO) has listed daclatasvir (DCV), symmetrical arene, as one of the essential medicines for human health. DCV manufacturing is usually carried out in a non-continuous or "batch" approach over multiple locations and is severely limited by long production times (3-10 days), resulting in non-affordability (highly expensive) and disruption of the potential chain supply. Here, we report the total process system including the development of a novel electro-flow reactor containing patterned electrodeposited Ni or Pt nanoparticles over a copper electrode for a C-C coupling reaction in a co-reductant/oxidant-free, ultra-fast process for symmetrical substituted/unsubstituted biphenyl synthesis. This method was further extended to a new generation commercial batch synthetic route for continuous flow ultra-fast daclatasvir synthesis in 33.2 min. We envisage that this micro-electro-flow reactor (μ-EFR) system platform will substantially enable advances in continuous-μ-flow fine chemical manufacturing, multistep reaction sequences, reaction devising equipment, and real-time extraction.

Synthetic method of daclatasvir

The invention discloses a synthetic method of daclatasvir. The method adopts bis(2-bromoacetyl) biphenyl and t-butyloxycarboryl-L-proline as initial raw materials, the initial raw materials are separately synthesized into a midbody N-4, N-3, N-2 and N-1 i

DACLATASVIR FREE BASE AND PROCESS FOR THE PREPARATION THEREOF

The present invention relates to daclatasvir free base, processes for its preparation, a process for its conversion into pharmaceutically acceptable salts of daclatasvir. The present invention also relates to a process for the preparation and purification

POLYMORPHIC FORMS OF METHYL((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((METHOXYCARBONYL)AMINO)-3-METHYLBUTANOYL)-2-PYRROLIDINYL)-1H-IMIDAZOL-5-YL)-4-BIPHENYLYL)-1H-IMIDAZOL-2-YL)-1-PYRROLIDINYL) CARBONYL)-2-METHYLPROPYL)CARBAMATE AND SALTS THEREOF

Amorphous methyl((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3- methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl) carbonyl)-2-methylpropyl) carbamate free base, amorphous methyl((1S)-1

STABLE AMORPHOUS DACLATASVIR DIHYDROCHLORIDE

The present invention provides a stable amorphous form of daclatasvir dihydrochloride and a process for its preparation. The present invention also provides an amorphous form of daclatasvir and a process for its preparation.

Method for preparing Daclatasvir

The invention provides a method for preparing Daclatasvir. According to the method disclosed by the invention, N-(methoxycarbonyl)-L-valine and 5,5'-(4,4'-biphenylyl)di(2-((2S)-2- pyrrolidinyl)-1hydrogen-imidazole)tetrahydrochloride are used as reaction m

PROCESS FOR THE PREPARATION OF DACLATASVIR

The present disclosure provides a novel process for the preparation of daclatasvir or pharmaceutically acceptable salts thereof using novel intermediates. Formula (I)

Daclatasvir synthetic method

The invention provides a daclatasvir synthetic method. The method comprises the following steps: taking 4,4'-di(2-halogenated acetyl)biphenyl as a raw material, performing an esterification reaction with N-(methoxycarbonyl)-L-valine-L-proline in an organic solvent under alkali existence to obtain an intermediate B; then performing a dehydrating-cyclizing reaction on the intermediate B and ammonium acetate in an xylene solution at the temperature of 100-120 DEG C to obtain free alkali C; and reacting the free alkali C and HCl to obtain a daclatasvir crude product; and finally re-crystallizing the daclatasvir crude product to obtain daclatasvir. The synthetic method has the advantages of simple synthesis route, convenient operation and simple purifying, the purity of daclatasvir obtained by the synthesis reaction is high, the yield is large, quality of the daclatasvir bulk drug is greatly increased, production cost is reduced, and the method is suitable for large industrial production.

Novel synthesis method of Daclatasvir

The invention relates to a novel synthesis method of Daclatasvir, particularly discloses an intermediate for preparing Daclatasvir and a preparation method of the intermediate, and provides a preparation method of Daclatasvir. The method is more economical and more efficient.

Novel method for synthesizing dimethyl dicarbamate dihydrochloride compound

The invention relates to a novel method for synthesizing N,N'[[1,1'-biphenyl]4, 4'-diyl bis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-ethylmethyl)-2-oxo-2,1-ethanediyl]]] dimethyl dicarbamate dihydrochloride. According to the novel method d